Trending Topic

Female Pelvic Anatomy Showing Ovarian Tumors
6 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Polycystic ovary syndrome (PCOS) is a complex, multisystemic condition characterized by reproductive, metabolic and dermatologic manifestations, including hyperandrogenism and ovulatory dysfunction. Despite its prevalence and significant impact on quality of life, PCOS remains underdiagnosed and poorly managed due to its heterogeneous presentation and the lack of a unified approach to care. PCOS affects approximately 6–20% […]

Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – aims and design

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 1st 2023

CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the mechanism of action of CM-101, and the aims, design and eligibility criteria of the proof-of-concept study.

The abstract entitled ‘Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.

Questions:

  1. What is the mechanism of action of CM-101? (0:14)
  2. What were the aims, design, and eligibility criteria of the study? (2:03)

Disclosures: Rifaat Safadi is a consultant for Chemomab.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.

Filmed in coverage of EASL 2023

Access further content on liver disorders

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup